Isoprostanes are currently used as biomarkers of lipid peroxidation in humans. 1 Minuz et al 2 recently showed that urinary levels of 15-F 2t -IsoP were increased in hypertensive patients suffering from renovascular disease, confirming the experimental data showing that renovascular hypertension and activation of the renin-angiotensin system in general is associated with an increased lipid peroxidation. Conversely, data obtained from 25 patients with essential hypertension showed that urinary levels of 15-F 2t -IsoP were not significantly different in comparison with controls. Similarly, we showed that the urinary levels of 15-F 2t -IsoP were not increased in untreated patients with mild-tomoderate hypertension. 3 In our study, the mean systolic and diastolic blood pressure was similar to Minuz's essential hypertensive patients, but because our patients were never treated, their hypertension was probably less severe. Both studies are consistent with the hypothesis that oxidative stress is not increased in the early stages of human essential hypertension. However, they do not rule out the possibility that essential hypertension is associated with an increased oxidative stress at later stages, as a consequence of hypertension. A large number of studies show that isoprostane levels are increased in cigarette smokers, homocystinemia, diabetes mellitus, and hypercholesterolemia. 4 We now have evidence that renovascular, but not essential, hypertension is associated with increased F 2 -isoprostane levels. It is likely that the increased levels observed are related to an increased production of these compounds rather than a variation of their clearance.
Response
We agree with the substance of Drs Cracowski's and Baguet's comments. In fact, our recently published study 1 did provide evidence for a pathophysiological role of F 2 -isoprostanes in mediating persistent platelet activation in patients with renovascular disease. This may reflect the biological activity of 8-iso-PGF 2␣ and other iso-eicosanoids in amplifying the platelet response to other agonists. 2 A similar relationship between enhanced formation of bioactive F 2 -isoprostanes and persistent platelet activation has been reported in association with hypercholesterolemia, 3 type 2 diabetes mellitus, 4 and visceral obesity. 5 Whether the rate of in vivo lipid peroxidation, as reflected by F 2 -isoprostane excretion, helps predict major vascular events is an interesting question that deserves further investigation. In the recent study of Davì et al, 5 the C-reactive protein level was linearly correlated with the excretion rate of 8-iso-PGF 2␣ in a group of otherwise healthy women with abdominal adiposity and free of other cardiovascular risk factors. Thus, the interplay between low-grade inflammation, lipid peroxidation, and platelet activation, as characterized in the paradigm of visceral obesity, may have broader implications for cardiovascular risk assessment and management. 
